

Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

INSTRUCTIONS: (Do not include this instruction page in your REB Submission)

1. REB Submission Requirements:

Applications to the Southlake Regional Health Centre Research Ethics Board (SRHC REB) must include the following documentation as applicable to the research project submitted for review. Incomplete submissions will not be processed (upon request).

- Certificates of completion for mandatory research ethics training as per SRHC policy.
- A signed and dated application form
- The protocol/research proposal (version clearly identified and dated) with accompanying study materials including but not limited to:
 - o Informed consent document (electronic copy must be in Word format)
 - o Product Monograph / Device Manual
 - o Qualified/Principal Investigator curriculum vitae (CV) (signed and dated)
 - o Any educational materials, advertisements/recruitment materials, questionnaires, etc. intended for research participants
 - o Data collection forms
 - o Study Budget

2. REB Submission Process/Contact Information:

Send signed REB Applications and related study materials via email to: rebsubmissions@southlakeregional.org

- Additional information about the SRHC REB, submission deadlines and standard operating procedures is available on the SRHC website.
- Inquiries/questions can be directed to the REB Administrator at 905-895-4521 ext. 6638 or via email.

3. Types of Research Qualifying as Minimal Risk:

- a) Secondary use of data: the use of data contained in records collected for a purpose other than the research itself (e.g. medical chart review) (Note: no REB approval is required for use of previously collected, publicly available, anonymized research data)
- b) Collection of biologic samples by non-invasive means (e.g., mouth swab) or taking additional blood samples for research at the time of clinically-indicated blood drawing. The allowable amount will be based on the age, weight, and health of the participants. No genetic testing is involved.
- c) Collection of data through non-invasive procedures routinely used in clinical practice not involving x-rays or microwaves (such as ECG, ultrasound, hearing testing, or moderate exercise).
- d) Research on individual or group characteristics or behavior (including, but not limited to, research on perception, cognition, motivation, identity, language, communication, cultural beliefs or practices, and social behavior).
- e) Research employing survey, interview, oral history, focus group or program evaluation. (invasive questions in vulnerable circumstances/ context or significant nuisance/inconvenience do not qualify)
- f) Biomedical clinical trials not subject to prior authorization by Health Canada involving:
 - i. Drugs or natural health products that are being used according to the approved labelling,
 - ii. Class I medical devices
 - iii. Phase IV biomedical clinical trials or observational studies involving natural health products that are being used according to the approved labelling.
 - iv. Biomedical clinical trials where the only difference from standard care is that research subjects are randomized among two or more existing current standards of intervention.

Note: If the REB determines that a research project submitted for delegated review does not meet minimal risk criteria, you will be required to complete a new application form for full board review



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

Date: mm / dd / yy

Original Application

Revised Application

1. IDENTIFICATION

a. Applicant Name: _____
 Affiliated Institution: _____
 Current Position at Institution: _____
 Mailing Address: _____
 Telephone: _____
 Email: _____

b. Full Study Title:

c. Protocol/Research Proposal Version Date/Number: _____

2. FUNDING

a. Industry Granting Agency Academic Funding Other Not Funded

b. Name of Funding Source: *(if applicable)* _____

3. GENERAL STUDY DESCRIPTION *(check all that apply)*

a. Is the study subject to Health Canada approval? Yes* No

*If YES above, please complete and submit the REB Application for Full Board Review

b. Observational Non-Interventional Registry Chart Review

Other: _____

c. Randomized Open Label Blinded Pilot Phase IV (Drugs/Biologics) N/A

d. Epidemiological Social Science Focus Group
 Student Project Needs Assessment Interviews
 Quality Improvement Cohort Study Creation of a Database
 Questionnaires/Surveys Non-Invasive Physical Measurements
 Use of Biological Specimens (e.g. blood, tissue) not involving genetic testing

e. Anticipated start date: mm / dd / yy



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

f. Anticipated duration of study: _____ years _____ months

g. Number of anticipated research participants:

i. Worldwide: _____

ii. At site: _____

4. RESEARCH SITE INFORMATION

a. Primary location of where the research will be conducted:

Southlake Regional Health Centre

Other: Institution/Site Name: _____

Address: _____

Telephone: _____

b. If any of the research procedures/study visits will be conducted at a secondary location (e.g. private healthcare provider office), please provide the details below:

Institution/Site Name: _____

Address: _____

Telephone: _____

Specify the procedures/study visits that will occur at the secondary location:

5. MULTI-INSTITUTIONAL RESEARCH

a. Does this study involve research sites outside the jurisdiction of the SRHC REB? Yes No

b. Has another ethics board or regulatory authority (including non-Canadian) reviewed this study leading to a negative decision (non-approval) OR leading to a request to modify the protocol/research proposal that is being submitted with this application?

Yes* No Unknown N/A – Research is only being conducted locally within the jurisdiction of SRHC REB

If YES* above, please provide the name of the ethics board or regulatory authority, the reasons and nature of the decision below and attached any relevant correspondence.

6. STUDY SUMMARY

a. Check the applicable category below:

Prospective Research: Research that involves future direct interaction and/or intervention with study participants.

If Prospective Research, continue to Section 7 and include a separate protocol/research proposal with your submission in accordance REB submission requirements.*



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

**Please ensure that the protocol/proposal clearly highlights standard of care versus the investigational aspects of the research.*

**A downloadable Minimal Risk Protocol template is available through the SRHC website. If you require assistance with developing a research protocol/proposal, please contact SRHC REB Administrator at 905-898-4521 ext. 6638.*

- Retrospective Research:** The use of information or human biological materials originally collected for a purpose other than that of this research such as administrative data or medical records. Looking back to answer the research question. The outcome of interest has already occurred (or not) by the time the study is started.

If Retrospective Research (e.g. chart review study), Section 6(b) below may be completed (only if space permits) in lieu of a separate research protocol/proposal.

b. Retrospective Research Synopsis:

1. Summary of Project:

2. Background:

3. Hypothesis *(if applicable)*:

4. Objectives:

5. Methods:



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

6. List data to be collected (*include data collection tool with your submission*):

7. Proposed Analysis:

8. Inclusion/Exclusion Criteria:

9. Anticipated "N" and sample size rationale:

10. Anticipated public and/or scientific benefit:

11. Identification of potential harms/risks that may occur through this research (e.g. breach of confidentiality) and how they will be managed:



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

7. RESEARCH TEAM

a. Qualified/Principal Investigator:

i. Same as Applicant listed on page 1? Yes No*

If NO* above, please complete the follow information below:

Investigator Name: _____

Affiliated Institution: _____

Current Position (Status): _____

Mailing Address: _____

Telephone: _____

Email: _____

ii. Any Disciplinary Actions or License Restrictions: Yes* No N/A

If YES* above, please describe:

b. Study Coordinator: (if applicable)

Study Coordinator Name: _____

Affiliated Institution: _____

Current Position (Status): _____

Mailing Address: _____

Telephone: _____

Email: _____

c. Additional Research Team Personnel: (if applicable)

NAME	CREDENTIALS	AFFILIATED INSTITUTION (e.g. SRHC)	PROJECT ROLE (e.g. Sub-Investigator, Study Coordinator, Research Assistant)	ACCESS TO IDENTIFIABLE IDENTIFYING OR INFORMATION? (Y/N)	SRHC Research SOP Training? (Y/N)



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

8. QUALIFIED/PRINCIPAL INVESTIGATOR TRAINING/EDUCATION

- a. Is a current copy of the Qualified/Principal Investigator CV on file with the SRHC Research Office?
 Yes No* (If NO*, please attach)
- b. List below the Qualified/Principal Investigator education/training for the ethical conduct of research involving humans (check all that apply and submit certificates of completion in accordance with SRHC policy):
- TCPS2 (CORE Web based Tutorial) GCP (Good Clinical Practice) Sponsor Training
- National Institutes of Health (NIH) Web-Based Training Course
- CITI (specify course): _____
- Other: _____
- None

9. DECLARATION OF CONFLICT OF INTEREST (COI)

- a. Does the Qualified/Principal Investigator or any other member of the research team have any real, potential or perceived conflict of interest (COI) to declare? (e.g. financial, personal, institutional, dual role as both the researcher and healthcare provider).
 Yes* No
- b. If YES* above:
- i. Name(s) of Individual(s) Declaring COI _____
- ii. Describe the nature of the COI:
- iii. What steps are planned by the Qualified/Principal Investigator to manage and/or minimize this conflict so that potential participants can make an informed autonomous decision?

10. PRIVACY AND CONFIDENTIALITY OF PERSONAL HEALTH INFORMATION (PHI)

- Identifiable Information: Information that may reasonably be expected to identify an individual (e.g. full name, health card number, health record number) or in combination with other available information (e.g. part of a date of birth and address).
- De-Identified Information: Originally collected with identifiers which have subsequently been removed and usually replaced with a code number or initials; a master list is kept linking the code number to the participant.
- Anonymized Information: Originally collected with identifiers which have subsequently been removed and no linkage to the participant.
- Anonymous Information: Originally collected without any identifiers therefore never associated or linked to an individual.

- a. Source(s) of PHI collection:
- Directly from study participant
- Indirectly from study participant (e.g. information from documents/records or human biological materials previously collected for medical treatment)



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

i. Identify the indirect source(s) of PHI:

- Hardcopy records
- Electronic records
- Databases
- Other: _____

b. Where are the sources of PHI located? (*check all that apply*)

- Site(s) where research is being conducted (as described in Section #4)
- Private Office (e.g. healthcare provider)
- Other: _____

c. Will identifiable PHI (information or biological specimens) be collected? Yes No

d. If PHI is shared and sent outside of your research site to any 3rd party (e.g. governmental agency, community research partner, study sponsor), will the information be de-identified or anonymized? Yes* No N/A

If YES* above, skip i-iii below and continue to Section #11

i. Explain why sending identifiable PHI outside of the research site is necessary to conduct the research:

ii. Indicate how the identifiable PHI will be transferred securely outside of the research site: (*check all that apply*)

- eCRF
- Web enabled
- Fax
- Encrypted Email
- Private Bonded Courier
- Registered Mail
- Other: _____

iii. What security measures by the recipient are in place to protect identifiable PHI that is transferred from the research site:

11. STUDY DATA SECURITY, STORAGE, RETENTION AND DISPOSAL

a. What is the method(s) of data storage at the research site? (*check all that apply*)

- Desktop computer
- Laptop computer
- USB Drive
- Hardcopy
- Other: _____



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

b. What security measures are in place to protect data at the research site? *(check all that apply)*

- Computer or Network Firewall
 Encryption
 Password
 Locked Hardcopy File
 Other: _____

c. How long will study data be stored at the research site?

- In accordance with institutional (hospital/site) standard operating procedures/policies
 Other: _____ *(specify duration)*

d. Will the study data be linked or combined with any other data sets? Yes* No

If YES* above:

- i. What other data set: _____
 ii. How linkage will be made: _____
 iii. Provide list of data elements: _____
 iv. If data sets are anonymous is there a reasonable prospect that the linkage could generate identifiable information?
 Yes No N/A

e. Secondary Use:

Will study data or biological specimens be stored for possible future research? Yes* No

If YES* above:

- i. Will informed consent be sought from study participants for possible secondary uses?
 Yes No
 ii. Where will the data or biological specimens be stored?
 iii. Who will have access? _____
 iv. Identify the security measures in place to provide protection and respect for the privacy of research participants

 v. Will the future use of study data or biological specimens be subject to ethical review/oversight?
 Yes No

12. INFORMED CONSENT

a. Is expressed (written) consent being obtained?

- Yes No*

****If NO above, and REB waiver or alteration of informed consent process is being requested, please complete i & ii below:***



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

i. Type of Request:

- Waiver of consent Alteration of consent process (e.g. No written consent)

ii. Please provide justification for waiver or alteration of informed consent: *(check all that apply)*

- The research involves no more than minimal risk to the participants;
 The lack of or alteration of the participant's consent is unlikely to adversely affect the welfare of the participant;
 It is impossible or impracticable to carry out the research and to answer the research question properly, given the research design, if the prior written consent of the participant is required;
 It will be possible and appropriate, after participation, at a later time during the study, to debrief study participants and provide them with additional pertinent information, at which point they will have the opportunity to refuse consent
 Other: _____

If WAIVER of consent is requested skip b to h and continue to Section 13.

If consent is obtained (eg. written, implied), continue with this section and complete b to h below:

b. What procedures will be followed to conduct the informed consent process? *(check all that apply)*

- SRHC SOPs/Policies Other *(please attached a copy)*

c. Identify the study personnel who will primarily be conducting the informed consent process:

- Study Coordinator Research Assistant Qualified/Principal Investigator Co/Sub Investigators
 N/A

d. Will consent be obtained from minors under 16 years of age? Yes* No N/A

(If YES above, an "assent" form should also be included with this submission)*

e. Will this study require the need for an Authorized Legal Representative to be involved in the informed consent process?

- Yes No *(i.e. Will any participants be unable to consent for themselves?)*

f. Will provisions be made to provide non-English speaking participants with information in a language understandable to them (both written and oral)?

- Yes No N/A – Only English speaking participants will be enrolled

g. Will the informed consent process be conducted in a location that will provide privacy for potential participants?

- Yes No N/A

h. Do you confirm that you will provide participants with a signed copy of the REB Approved study information and consent form, sufficient time to read the document to consider participation, and ample opportunity to have their questions answered by a qualified/knowledgeable member of the research team? Yes No N/A



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

13. STUDY POPULATION

- a. Healthy Volunteers
 Volunteers being treated for a medical condition: _____ (specify)

- b. Will recruitment materials be utilized? (e.g. posters, advertisements) Yes* No

If YES* above, REB approval is required.

- c. Will any individuals be excluded from the research based on demographic factors such as age, gender or race?
 Yes* No

If YES* above, please explain: _____

- d. Will the study participants be recruited from within the primary or secondary research site(s) as specified on this application?
 Yes No (please specify where) _____

- e. Will any vulnerable populations (see definition below) **within the context of this research** be enrolled? Yes No*

Vulnerable Populations: Individuals whose specific circumstances may limit their ability to fully safeguard their own interests or whose willingness to volunteer in the research may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation. Vulnerability is often caused by limited capacity, or limited access to social goods, such as rights, opportunities and power.

If NO* above, Continue to Section #14.

- f. Specify the vulnerable population(s) to be enrolled: (check all that apply)

- Minors/Children
 Economically or educationally disadvantaged participants
 Participants unable to consent for themselves
 Participants with diminished decision making capacity
 Incapable of legally informed consent
 People experiencing an immediate medical emergency
 Employees of the institution (site/hospital)
 Pregnant Women
 Other: Specify: _____

- g. Is the vulnerable population the primary research population? Yes No*

- h. If NO* above:

- i. Justify the inclusion of vulnerable persons if not required to meet study objectives:



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

ii. How will the vulnerable population(s) be treated differently in order to protect their rights and welfare?

iii. How will informed consent be obtained from the vulnerable population?

14. PARTICIPANT COMPENSATION

Will any compensation, incentives or reimbursement of expenses be available to participants?

Yes* No

If YES* above, please provide details including amounts and frequency of payment(s) (e.g. per study visit):

15. PUBLICATION AND DISSEMINATION OF RESULTS

a. Does the sponsor/funding agency place any restrictions on the publication or reporting of results that in any way limit the negative outcome reporting of the Qualified/Principal Investigator?

Yes* No N/A

b. If YES* above, please specify the restrictions:

c. Describe how the results of this study will be made publicly available: N/A

i. Peer/Scientific Journal

Peer/Conference Presentation

Other: _____

ii. Describe any additional methods that may be used to share study results with study participants: *(if applicable)*

16. AGREEMENTS

a. Is there a Clinical Trial Agreement for this study?

Yes No Pending

b. Is there a Data Sharing Agreement for this study?

Yes No Pending

c. Is there a Material Transfer Agreement?

Yes No Pending



Research Department

SRHC Research Ethics Board Application for Delegated (Expedited) Review: Minimal Risk Research Involving Humans

17. ATTESTATION OF QUALIFIED/PRINCIPAL INVESTIGATOR

I agree to abide by and comply with ethical standards, legislation, guidelines, and procedural requirements of Southlake Regional Health Centre and the Southlake Regional Health Centre Research Ethics Board; of the Tri-Council Policy Statement, of my profession, and of those of any other institution in which this research is undertaken. I am entitled to provide health care under the applicable laws and in good standing with my respective regulatory authority (if applicable).

I am aware of my responsibilities as the Qualified/Principal Investigator to:

- be familiar with the required standards, guidelines, policies and applicable legislation
- monitor the research to ensure that it is conducted in an ethical manner
- notify the SRHC REB of any unanticipated issues or changes to the research
- comply with any requests made by the SRHC REB during the life of the research and abide by REB reporting requirements such as annual renewal of research, unanticipated problems, deviations and notice of study closure
- supervise all team members and ensure that they are well versed in the conduct of ethical research

Name of Qualified/Principal Investigator: *(print first, last)*

Signature:

Date: mm / dd / yy

Name of person completing this form: *(print first, last)*

Signature:

Date: mm / dd / yy

